Wahl D - Search Results

1

Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria.

Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo MC, Avcin T, Bertolaccini ML, Branch DW, de Jesus G, Devreese KMJ, Frances C, Garcia D, Guillemin F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Seshan SV, Tektonidou M, Wahl D, Willis R, Naden R, Costenbader K, Erkan D; New APS Classification Criteria Collaborators. Barbhaiya M, et al. Among authors: wahl d. Arthritis Care Res (Hoboken). 2021 Oct;73(10):1490-1501. doi: 10.1002/acr.24520. Epub 2021 Sep 2. Arthritis Care Res (Hoboken). 2021. PMID: 33253499 Free PMC article. Review.

2

Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis.

Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Wahl DG, et al. Lupus. 1997;6(5):467-73. doi: 10.1177/096120339700600510. Lupus. 1997. PMID: 9229367

3

Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis.

Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Wahl DG, et al. Lupus. 1998;7(1):15-22. doi: 10.1191/096120398678919688. Lupus. 1998. PMID: 9493144

4

Antibodies against phospholipids and beta 2-glycoprotein I increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus.

Wahl DG, De Maistre E, Guillemin F, Regnault V, Perret-Guillaume C, Lecompte T. Wahl DG, et al. QJM. 1998 Feb;91(2):125-30. doi: 10.1093/qjmed/91.2.125. QJM. 1998. PMID: 9578894

5

Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis.

Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Wahl DG, et al. Arch Intern Med. 2000 Jul 10;160(13):2042-8. doi: 10.1001/archinte.160.13.2042. Arch Intern Med. 2000. PMID: 10888978

6

Antiphospholipid antibodies and risk for recurrent vascular events.

Wahl D, Regnault V, de Moerloose P, Lecompte T. Wahl D, et al. JAMA. 2004 Jun 9;291(22):2701-2; author reply 2702-3. doi: 10.1001/jama.291.22.2701-c. JAMA. 2004. PMID: 15187047 No abstract available.

7

Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation.

Regnault V, Boehlen F, Ozsahin H, Wahl D, de Groot PG, Lecompte T, de Moerloose P. Regnault V, et al. Among authors: wahl d. J Thromb Haemost. 2005 Jun;3(6):1243-9. doi: 10.1111/j.1538-7836.2005.01270.x. J Thromb Haemost. 2005. PMID: 15946215 Free article.

8

[Management of antiphospholipid syndrome].

Saadoun D, Piette JC, Wahl D, Costedoat-Chalumeau N. Saadoun D, et al. Among authors: wahl d. Rev Med Interne. 2012 Apr;33(4):217-22. doi: 10.1016/j.revmed.2012.01.007. Epub 2012 Feb 21. Rev Med Interne. 2012. PMID: 22360832 Review. French.

9

Severe and diffuse arterial lesions in a patient with pseudoxanthoma elasticum.

Zuily S, Angioi K, Fauret AL, Golmard L, Saadi L, Huttin O, Anxionnat R, Evon P, Marie PY, Jeunemaitre X, Wahl D. Zuily S, et al. Among authors: wahl d. J Am Coll Cardiol. 2012 May 29;59(22):1991. doi: 10.1016/j.jacc.2011.11.067. J Am Coll Cardiol. 2012. PMID: 22624841 Free article. No abstract available.

10

APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking.

Erkan D, Lockshin MD; APS ACTION members. Erkan D, et al. Lupus. 2012 Jun;21(7):695-8. doi: 10.1177/0961203312437810. Lupus. 2012. PMID: 22635205 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

563 results

Search Page

Filters